No connection

Search Results

BDMD vs INCR

BDMD
Baird Medical Investment Holdings Limited
BEARISH
Price
$1.03
Market Cap
$37.8M
Sector
Healthcare
AI Confidence
92%
INCR
InterCure Ltd.
BEARISH
Price
$0.76
Market Cap
$41.7M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
BDMD
--
INCR
--
Forward P/E
BDMD
--
INCR
-0.52
P/B Ratio
BDMD
0.77
INCR
0.1
P/S Ratio
BDMD
1.19
INCR
--
EV/EBITDA
BDMD
51.6
INCR
--

Profitability

Gross Margin
BDMD
86.94%
INCR
16.71%
Operating Margin
BDMD
-131.3%
INCR
0.0%
Profit Margin
BDMD
-9.95%
INCR
-29.18%
ROE
BDMD
-8.03%
INCR
-16.68%
ROA
BDMD
-0.2%
INCR
-7.74%

Growth

Revenue Growth
BDMD
-39.4%
INCR
3.4%
Earnings Growth
BDMD
--
INCR
--

Financial Health

Debt/Equity
BDMD
0.63
INCR
0.41
Current Ratio
BDMD
1.71
INCR
1.85
Quick Ratio
BDMD
1.22
INCR
1.08

Dividends

Dividend Yield
BDMD
--
INCR
--
Payout Ratio
BDMD
0.0%
INCR
0.0%

AI Verdict

BDMD BEARISH

The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of just 3/9, indicating poor financial health. Despite a seemingly reasonable Price/Book of 0.77 and a strong Gross Margin of 86.94%, the company is deeply unprofitable with negative operating and net margins, collapsing revenue, and no analyst coverage. The complete absence of Altman Z-Score and intrinsic value calculations, combined with a 5-year return of -89.3%, signals severe distress. Technical indicators and insider sentiment are also weak, reinforcing a high-risk outlook.

Strengths
High gross margin of 86.94% suggests strong pricing power or low production costs in core operations
Current ratio of 1.71 indicates short-term liquidity is manageable
Quick ratio of 1.22 shows the company can meet immediate obligations without relying on inventory
Risks
Piotroski F-Score of 3/9 indicates severe financial weakness and high risk of continued underperformance
Operating margin of -131.30% reflects deep operational inefficiencies or unsustainable cost structure
Revenue growth YoY of -39.40% shows rapid top-line contraction
INCR BEARISH

InterCure Ltd. exhibits severe financial distress as evidenced by a weak Piotroski F-Score of 2/9, indicating poor operational efficiency and financial health. Despite a very low Price-to-Book ratio of 0.10, the company is trapped in a catastrophic long-term price decline, losing over 91% of its value over five years. Negative profit margins and crashing EPS growth suggest that the low valuation is a value trap rather than a bargain. The lack of analyst coverage and a 0/100 technical trend further reinforce a bearish outlook.

Strengths
Low Debt-to-Equity ratio (0.41) suggests manageable leverage
Current Ratio of 1.85 indicates adequate short-term liquidity
Positive Gross Margin (16.71%) shows core product viability
Risks
Severe operational weakness indicated by Piotroski F-Score of 2/9
Negative profit margins (-29.17%) and negative ROE (-16.68%)
Catastrophic price performance (-91.7% over 5 years)

Compare Another Pair

BDMD vs INCR: Head-to-Head Comparison

This page compares Baird Medical Investment Holdings Limited (BDMD) and InterCure Ltd. (INCR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile